The company has 71.0 months of cash left based on the quarterly cash burn of $821.629 k and estimated current cash of $19.425 M

Bellevue Life Sciences Acquisition Corp. faces significant liquidity challenges, with a working capital deficit of $3,901,465 and only $12,236 in its operating bank account as of September 30, 2024. The company has extended its deadline to complete a business combination to February 14, 2025, but substantial doubt exists about its ability to continue as a going concern if it fails to secure additional funding or complete a business combination by this date. The company has issued several promissory notes and plans to raise capital through a $20 million PIPE investment, but these measures may not be sufficient to meet its financial obligations., Filed At: 2024-11-14